Three Days Off Upadacitinib Before a Knee That Won't Wait
A man whose only durable control of severe atopic dermatitis has come from upadacitinib needs a scheduled knee replacement — and the perioperative hold guidance he's being told to follow was written for rheumatoid arthritis, not for the disease he actually has.
Simon K., 58, taught high school shop class for over two decades before a knee injured on the job years ago finally progressed to end-stage osteoarthritis bad enough that his orthopedic surgeon has scheduled a total knee replacement for three weeks from now. His atopic dermatitis has been present since childhood, but the last five years were the worst of his adult life — widespread, weeping, unrelenting eczema that cost him sleep, cracked his hands badly enough to make grading papers painful, and failed two biologics before upadacitinib brought his EASI score down from 34 to 3 within eight weeks and kept it there for the fourteen months since.
The orthopedic team's standard pre-operative checklist flags upadacitinib for a hold, citing the 2022 ACR/AAHKS perioperative guideline, which recommends withholding JAK inhibitors for at least three days before elective surgery — shortened from the seven days the 2017 version advised, after trial data showed disease activity rebounding faster than the earlier interval assumed — on infection-risk grounds drawn from inflammatory arthritis and lupus populations undergoing hip or knee arthroplasty. The guideline is explicit that this recommendation addresses periprosthetic joint infection and does not account for venous thromboembolism or cardiac events at all. Simon has never had a rheumatologic flare to compare against, but he has a vivid, recent memory of what missing even a few doses does to his skin — a dosing gap during an insurance authorization lapse last year produced a flare severe enough to require a course of oral prednisone within ten days. He isn't asking to skip the hold; he's asking whether anyone has actually checked that the interval written for a different disease still fits his.
He has already rearranged his summer around this surgery, timing it to the six weeks between the end of the school year and the start of a woodworking class he teaches at the community college — a schedule that has no real slack in it if recovery runs long, and even less if a bad flare during the hold makes rehab harder to tolerate. His knee itself is unambiguously ready: imaging shows bone-on-bone degeneration in the medial compartment, and he has been managing daily pain at a level his surgeon calls unusually stoic for how advanced the joint disease actually is.
A guideline written for a different joint
I'd like to hold upadacitinib for the window the 2022 ACR/AAHKS guideline actually recommends — at least three days before his knee replacement, which is what that guideline shortened its own seven-day figure to once the flare data came in. The periprosthetic joint infection concern behind it is a drug-class effect, not a rheumatoid-arthritis-specific one; JAK1 inhibition systemically dampens the same immune surveillance regardless of which disease brought him to the drug. I'll say plainly that the guideline disclaims any read on venous thromboembolism, so I'm not resting on that.
I don't dispute the mechanism, but I'd point out that the guideline's actual risk-benefit weighing — how much a hold is worth given what a flare during it costs — was built entirely around rheumatoid arthritis, where an undertreated flare risks progressive joint damage. Simon's flare risk is real and unpleasant, evidenced directly by his own history, but it isn't the same category of harm; nobody has actually studied whether the same hold length is the right balance point for atopic dermatitis specifically.
I'm not arguing to shorten the hold below what the surgical safety data require — I'm flagging that we're borrowing half of a guideline (the interval) without the half that justified it (the disease-specific flare cost), and that gap is worth being honest about rather than treating the number as settled.
I'd separate the two questions the way the disagreement is already implicitly doing: the hold length itself should track the mechanism — systemic JAK1 blockade's effect on clotting and wound-healing surveillance, which doesn't care what disease the drug is treating — so I'd keep the guideline's interval as written rather than shorten it on dermatology-specific grounds we don't have data for. What should be disease-specific is the plan for managing the skin during the gap: topical corticosteroid stepped up preemptively rather than reactively, and a same-day restart plan once his surgical team clears wound healing, so the gap costs him as little control as the surgery allows without changing the safety interval itself.
Agreed: upadacitinib held for 3 days pre-operatively per the current ACR/AAHKS interval, with a pre-emptive topical corticosteroid step-up plan to blunt the flare Simon's own history predicted, and a wound-healing-gated (not calendar-gated) restart plan.
Not agreed, and named directly rather than papered over: whether a dermatology-specific perioperative guideline, with its own flare-cost data, should eventually replace the borrowed rheumatology interval for patients like Simon. The dermatologist thought this was worth raising with the ACR/AAHKS working group as a real gap; the orthopedic surgeon agreed the gap was real but wasn't willing to treat this one case as grounds to deviate from the only vetted interval that currently exists.